Mark Frame
Analyst
TD Cowen
Equibles does not estimate personal net worth.
About Mark Frame
Mark Frame is recorded as Analyst at TD Cowen. Mark Frame has spoken on 1 earnings call and 1 other investor event across 2 companies, most recently for Revolution Medicines, Inc. on May 6, 2026. Those appearances were for Revolution Medicines, Inc. (RVMD) and Nektar Therapeutics (NKTR). The companies whose calls Mark Frame spoke on are classified in the Healthcare sector.
Mark Frame on recent calls
“Maybe following up a little bit on Corey's question earlier, just on the Zoldan RASA plus Drax and RASA combo, can you maybe speak to the 309 design, particularly in light of the 302 finding and, you know, the survival data, I mean, looking better than anything we've ever seen, even in first line, just why is 309…”
“Maybe I recognize some of this will get informed by seeing some of that off-treatment data, but just for the company, can you kind of walk through your current assumptions on how you would approach kind of maintenance dosing and then for the physician similarly you know how how are you expecting to use this in the…”
Affiliation history
-
TD Cowen
Analyst
Transcript header (unverified)
Current
Company network
Nektar Therapeutics
NKTR
Biotechnology · Healthcare
1 appearance
Latest appearance 2026-04-20
View calls and events